Published: Thu, June 07, 2018
Medicine | By Douglas Stevenson

Naloxone recall due to particulate matter

Naloxone recall due to particulate matter

A recall for naloxone was issued by the Food and Drug Administration over fear that products from the company Hospira Inc. contain potentially risky loose particles.

The FDA said on Monday that the Naloxone recall was prompted by the potential for "loose particulate matter on the syringe plunger", which could result in a range of adverse effects.

Hospira says it has received no reports of issues or injuries from the recalled syringes.

See the full recall details.

As per the FDA, those who administer the Naloxone drug should check it for any particulate matter or discoloration before injecting it to a person. Adverse events related to these lots are unlikely, according to the US Food and Drug Administration, and may be as mild as local irritation, but may also include pulmonary dysfunction, emboli, infarction, or toxicity.

The recalled lots were distributed nationwide to wholesalers, distributors, and hospitals in the United States, Puerto Rico, and Guam from February 2017 to February 2018.

The voluntary recall by the Pfizer subsidiary is for Carpuject single-use cartridge syringe system of naloxone hydrochloride injection, USP.

People can survive an overdose, but it comes down to timing. The drug is known to restore the respiration to a person who stops breathing due to the overdose.

Hospira is asking distributors and retailers to discontinue using and distributing the recalled product.

The products being recalled have the following lot numbers: 72680LL and 76510LL.

Like this: